Guidelines for the management of familial hypercholesterolemia

Mariko Harada-Shiba, Hidenori Arai, Shinichi Oikawa, Takao Ohta, Tomoo Okada, Tomonori Okamura, Atsushi Nohara, Hideaki Bujo, Koutaro Yokote, Akihiko Wakatsuki, Shun Ishibashi, Shizuya Yamashita

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD is very high in these patients, they should be identified at an early stage of their lives and started on intensive treatment to control LDL-cholesterol. We here introduce a new guideline for the management of FH patients in Japan intending to achieve better control to prevent CAD. Diagnostic criteria for heterozygous FH are 2 or more of 1) LDL-cholesterol ≥180 mg/dL, 2) tendon/skin xanthoma(s), and 3) family history of FH or premature CAD within second degree relatives, for adults; and to have both 1) LDL-cholesterol ≥140 mg/dL and 2) family history of FH or premature CAD within second degree relatives, for children. For the treatment of adult heterozygous FH, intensive lipid control with statins and other drugs is necessary. Other risks of CAD, such as smoking, diabetes mellitus, hypertension etc., should also be controlled strictly. Atherosclerosis in coronary, carotid, or peripheral arteries, the aorta and aortic valve should be screened periodically. FH in children, pregnant women, and women who wish to bear a child should be referred to specialists. For homozygotes and severe heterozygotes resistant to drug therapies, LDL apheresis should be performed. The treatment cost of homozygous FH is authorized to be covered under the program of Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labour, and Welfare.

Original languageEnglish
Pages (from-to)1043-1060
Number of pages18
JournalJournal of Atherosclerosis and Thrombosis
Volume19
Issue number12
DOIs
Publication statusPublished - 2012

Fingerprint

Hyperlipoproteinemia Type II
Coronary Artery Disease
Guidelines
LDL Cholesterol
Xanthomatosis
Tendons
LDL Lipoproteins
Skin
Drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inborn Genetic Diseases
Blood Component Removal
Homozygote
Heterozygote
Medical problems
Aortic Valve
Health Care Costs
Aorta
Pregnant Women
Diabetes Mellitus

Keywords

  • Achilles tendon thickness
  • Coronary artery disease
  • Diagnosis criteria
  • LDL cholesterol
  • LDL receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Biochemistry, medical

Cite this

Harada-Shiba, M., Arai, H., Oikawa, S., Ohta, T., Okada, T., Okamura, T., ... Yamashita, S. (2012). Guidelines for the management of familial hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 19(12), 1043-1060. https://doi.org/10.5551/jat.14621

Guidelines for the management of familial hypercholesterolemia. / Harada-Shiba, Mariko; Arai, Hidenori; Oikawa, Shinichi; Ohta, Takao; Okada, Tomoo; Okamura, Tomonori; Nohara, Atsushi; Bujo, Hideaki; Yokote, Koutaro; Wakatsuki, Akihiko; Ishibashi, Shun; Yamashita, Shizuya.

In: Journal of Atherosclerosis and Thrombosis, Vol. 19, No. 12, 2012, p. 1043-1060.

Research output: Contribution to journalArticle

Harada-Shiba, M, Arai, H, Oikawa, S, Ohta, T, Okada, T, Okamura, T, Nohara, A, Bujo, H, Yokote, K, Wakatsuki, A, Ishibashi, S & Yamashita, S 2012, 'Guidelines for the management of familial hypercholesterolemia', Journal of Atherosclerosis and Thrombosis, vol. 19, no. 12, pp. 1043-1060. https://doi.org/10.5551/jat.14621
Harada-Shiba, Mariko ; Arai, Hidenori ; Oikawa, Shinichi ; Ohta, Takao ; Okada, Tomoo ; Okamura, Tomonori ; Nohara, Atsushi ; Bujo, Hideaki ; Yokote, Koutaro ; Wakatsuki, Akihiko ; Ishibashi, Shun ; Yamashita, Shizuya. / Guidelines for the management of familial hypercholesterolemia. In: Journal of Atherosclerosis and Thrombosis. 2012 ; Vol. 19, No. 12. pp. 1043-1060.
@article{21cb74ffb05d41b19de920f59a83cf3b,
title = "Guidelines for the management of familial hypercholesterolemia",
abstract = "Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD is very high in these patients, they should be identified at an early stage of their lives and started on intensive treatment to control LDL-cholesterol. We here introduce a new guideline for the management of FH patients in Japan intending to achieve better control to prevent CAD. Diagnostic criteria for heterozygous FH are 2 or more of 1) LDL-cholesterol ≥180 mg/dL, 2) tendon/skin xanthoma(s), and 3) family history of FH or premature CAD within second degree relatives, for adults; and to have both 1) LDL-cholesterol ≥140 mg/dL and 2) family history of FH or premature CAD within second degree relatives, for children. For the treatment of adult heterozygous FH, intensive lipid control with statins and other drugs is necessary. Other risks of CAD, such as smoking, diabetes mellitus, hypertension etc., should also be controlled strictly. Atherosclerosis in coronary, carotid, or peripheral arteries, the aorta and aortic valve should be screened periodically. FH in children, pregnant women, and women who wish to bear a child should be referred to specialists. For homozygotes and severe heterozygotes resistant to drug therapies, LDL apheresis should be performed. The treatment cost of homozygous FH is authorized to be covered under the program of Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labour, and Welfare.",
keywords = "Achilles tendon thickness, Coronary artery disease, Diagnosis criteria, LDL cholesterol, LDL receptor",
author = "Mariko Harada-Shiba and Hidenori Arai and Shinichi Oikawa and Takao Ohta and Tomoo Okada and Tomonori Okamura and Atsushi Nohara and Hideaki Bujo and Koutaro Yokote and Akihiko Wakatsuki and Shun Ishibashi and Shizuya Yamashita",
year = "2012",
doi = "10.5551/jat.14621",
language = "English",
volume = "19",
pages = "1043--1060",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "12",

}

TY - JOUR

T1 - Guidelines for the management of familial hypercholesterolemia

AU - Harada-Shiba, Mariko

AU - Arai, Hidenori

AU - Oikawa, Shinichi

AU - Ohta, Takao

AU - Okada, Tomoo

AU - Okamura, Tomonori

AU - Nohara, Atsushi

AU - Bujo, Hideaki

AU - Yokote, Koutaro

AU - Wakatsuki, Akihiko

AU - Ishibashi, Shun

AU - Yamashita, Shizuya

PY - 2012

Y1 - 2012

N2 - Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD is very high in these patients, they should be identified at an early stage of their lives and started on intensive treatment to control LDL-cholesterol. We here introduce a new guideline for the management of FH patients in Japan intending to achieve better control to prevent CAD. Diagnostic criteria for heterozygous FH are 2 or more of 1) LDL-cholesterol ≥180 mg/dL, 2) tendon/skin xanthoma(s), and 3) family history of FH or premature CAD within second degree relatives, for adults; and to have both 1) LDL-cholesterol ≥140 mg/dL and 2) family history of FH or premature CAD within second degree relatives, for children. For the treatment of adult heterozygous FH, intensive lipid control with statins and other drugs is necessary. Other risks of CAD, such as smoking, diabetes mellitus, hypertension etc., should also be controlled strictly. Atherosclerosis in coronary, carotid, or peripheral arteries, the aorta and aortic valve should be screened periodically. FH in children, pregnant women, and women who wish to bear a child should be referred to specialists. For homozygotes and severe heterozygotes resistant to drug therapies, LDL apheresis should be performed. The treatment cost of homozygous FH is authorized to be covered under the program of Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labour, and Welfare.

AB - Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD is very high in these patients, they should be identified at an early stage of their lives and started on intensive treatment to control LDL-cholesterol. We here introduce a new guideline for the management of FH patients in Japan intending to achieve better control to prevent CAD. Diagnostic criteria for heterozygous FH are 2 or more of 1) LDL-cholesterol ≥180 mg/dL, 2) tendon/skin xanthoma(s), and 3) family history of FH or premature CAD within second degree relatives, for adults; and to have both 1) LDL-cholesterol ≥140 mg/dL and 2) family history of FH or premature CAD within second degree relatives, for children. For the treatment of adult heterozygous FH, intensive lipid control with statins and other drugs is necessary. Other risks of CAD, such as smoking, diabetes mellitus, hypertension etc., should also be controlled strictly. Atherosclerosis in coronary, carotid, or peripheral arteries, the aorta and aortic valve should be screened periodically. FH in children, pregnant women, and women who wish to bear a child should be referred to specialists. For homozygotes and severe heterozygotes resistant to drug therapies, LDL apheresis should be performed. The treatment cost of homozygous FH is authorized to be covered under the program of Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labour, and Welfare.

KW - Achilles tendon thickness

KW - Coronary artery disease

KW - Diagnosis criteria

KW - LDL cholesterol

KW - LDL receptor

UR - http://www.scopus.com/inward/record.url?scp=84871869008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871869008&partnerID=8YFLogxK

U2 - 10.5551/jat.14621

DO - 10.5551/jat.14621

M3 - Article

VL - 19

SP - 1043

EP - 1060

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 12

ER -